Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Department of Antisense Drug Discovery, ISIS Pharmaceuticals, Inc., Carlsbad, California.
Cancer Res. 2015 Oct 1;75(19):4235-43. doi: 10.1158/0008-5472.CAN-15-0964. Epub 2015 Aug 3.
Thrombin-mediated proteolysis is a major determinant of metastasis, but is not universally important for primary tumor growth. Here, we report that colorectal adenocarcinoma represents one important exception whereby thrombin-mediated functions support both primary tumor growth and metastasis. In contrast with studies of multiple nongastrointestinal cancers, we found that the growth of primary tumors formed by murine and human colon cancer cells was reduced in mice by genetic or pharmacologic reduction of circulating prothrombin. Reduced prothrombin expression was associated with lower mitotic indices and invasion of surrounding tissue. Mechanistic investigations revealed that thrombin-driven colonic adenocarcinoma growth relied upon at least two targets of thrombin-mediated proteolysis, protease-activated receptor-1 (PAR-1) expressed by stromal cells and the extracellular matrix protein, fibrinogen. Colonic adenocarcinoma growth was reduced in PAR-1-deficient mice, implicating stromal cell-associated PAR-1 as one thrombin target important for tumor outgrowth. Furthermore, tumor growth was dramatically impeded in fibrinogen-deficient mice, offering the first direct evidence of a critical functional role for fibrinogen in malignant tumor growth. Tumors harvested from fibrinogen-deficient mice displayed a relative reduction in cell proliferative indices, as well as increased tumor necrosis and decreased tumor vascular density. Collectively, our findings established a functional role for thrombin and its targets PAR-1 and fibrinogen in the pathogenesis of colonic adenocarcinoma, supporting tumor growth as well as local invasion and metastasis.
凝血酶介导的蛋白水解是转移的主要决定因素,但对原发性肿瘤生长并非普遍重要。在这里,我们报告结直肠腺癌是一个重要的例外,凝血酶介导的功能支持原发性肿瘤生长和转移。与多种非胃肠道癌症的研究不同,我们发现,通过遗传或药理学降低循环凝血酶原,可减少由小鼠和人结肠癌细胞形成的原发性肿瘤的生长。凝血酶原表达减少与较低的有丝分裂指数和周围组织的侵袭有关。机制研究表明,凝血酶驱动的结直肠腺癌生长依赖于至少两个凝血酶介导的蛋白水解的靶标,即基质细胞表达的蛋白酶激活受体-1(PAR-1)和细胞外基质蛋白纤维蛋白原。PAR-1 缺陷型小鼠中的结直肠腺癌生长减少,提示基质细胞相关的 PAR-1 是肿瘤生长的一个重要的凝血酶靶标。此外,纤维蛋白原缺陷型小鼠中的肿瘤生长显著受阻,为纤维蛋白原在恶性肿瘤生长中的关键功能作用提供了首个直接证据。从纤维蛋白原缺陷型小鼠中收获的肿瘤显示出细胞增殖指数相对降低,肿瘤坏死增加,肿瘤血管密度降低。总的来说,我们的发现确立了凝血酶及其靶标 PAR-1 和纤维蛋白原在结直肠腺癌发病机制中的功能作用,支持肿瘤生长以及局部侵袭和转移。